# Qi Biodesign

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qi-biodesign

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Total disclosed funding: $58M
- Latest round: Series A (May 6, 2026)
- Investors on record: 12

## About

Established in 2021 and based in Suzhou, China, Beijing Qihe Biotechnology Co., Ltd., trading as Qi Biodesign, operates as a biotechnology company that focuses on the R&D of gene editing technology for plant breeding. The company was established by Doctor Kevin Zhao and gene editing scientist Caixia Gao. It acquired 2 Chinese Plant Gene Editing Safety Certificates and the US USDA Exempt Gene Editing Product Certification. In May 2026, Qi Biodesign raised over CNY 100 million in Series A+ funding led by CITIC Agriculture, with participation from Confitop Capital, Construction Future Fund, Nanjing Innovation Capital Group, Starbucks Fund.
Qi Biodesign's main business is the research and development and application of gene editing technology. Develop new gene editing technologies to create excellent biological traits and products. The company has built the SEEDIT™ biotechnology and trait engineering platform. The platform can achieve multiple gene or genome operations such as precise gene knockout, base substitution, fine regulation of gene expression, and precise insertion of large DNA fragments. The company has established an independent and efficient delivery system for more than 40 crops.
The company generates revenue by providing gene editing technologies and related services.
The Series A+ funding will primarily be used for iterating core gene editing technologies, advancing the product pipeline, commercialization, and global market expansion.

## Funding rounds

- Series A, May 6, 2026, $15M — CITIC Agriculture, Nanjing Innovation Capital Group, Confitop Capital
- Series A, Dec 2, 2024, $28M — Gaorong Ventures, Source Code Capital, CD Capital, Casstar Capital, Apricot Capital, Changkejin  Investment, Shunxi Fund, Shang Qi Capital, Mingzhe Asset
- Seed, Mar 21, 2022, $16M — Apricot Capital

## Investors

- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Seed, Series A
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series A
- Source Code Capital (https://capitalatlas.ai/funds/source-code-capital) — Series A
- CD Capital — Series A
- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Series A
- Changkejin  Investment — Series A
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series A
- Shang Qi Capital (https://capitalatlas.ai/funds/shang-qi-capital) — Series A
- Mingzhe Asset (https://capitalatlas.ai/funds/mingzhe-asset) — Series A
- CITIC Agriculture (https://capitalatlas.ai/funds/citic-agriculture) — Series A
- Nanjing Innovation Capital Group — Series A
- Confitop Capital (https://capitalatlas.ai/funds/confitop-capital) — Series A